Gaétan Gravel
Directeur/Membre du Conseil chez GLyPharma Therapeutic, Inc.
Profil
Mr. Gaétan Gravel is a Portfolio Manager at Fonds de Solidarité FTQ.
He is on the Board of Directors at Thrasos Therapeutics, Inc. and GLyPharma Therapeutic, Inc.
Mr. Gravel was previously employed as a Director-Customer Services & Development by Business Development Bank of Canada.
He also served on the board at Mirati Therapeutics, Inc.
Mr. Gravel received his undergraduate degree from HEC Montréal.
Postes actifs de Gaétan Gravel
| Sociétés | Poste | Début |
|---|---|---|
Fonds de Solidarité FTQ
 Fonds de Solidarité FTQ Investment ManagersFinance Fonds de Solidarité FTQ (Fonds Régional de Solidarité FTQ) is a private equity firm founded in June 1983. The firm is headquartered in Montréal, Quebec. | Private Equity Investor | 20/11/2010 |
GLyPharma Therapeutic, Inc.
 GLyPharma Therapeutic, Inc. BiotechnologyHealth Technology GLyPharma Therapeutic, Inc. develops oncology therapeutic treatment. It engages in the development of the clinical efficacy of FE 203799, a novel proprietary Glucagon-Like Peptide-2(GLP-2) analogue exerting unique pharmacological effects in a first-in-class, meaningful indication for patients with hematological malignancies receiving myelotoxic therapies. The company was founded in August 2012 and is headquartered in Montreal, Canada. | Directeur/Membre du Conseil | - |
Anciens postes connus de Gaétan Gravel
| Sociétés | Poste | Fin |
|---|---|---|
Business Development Bank of Canada
 Business Development Bank of Canada Finance/Rental/LeasingFinance Business Development Bank of Canada provides commercial banking services. It offers business loans and consulting services to help Canadian businesses grow, both at home and abroad. The firm also offers a full spectrum of specialized financing, including venture capital, equity as well as growth and business transition capital through its subsidiaries. The company was founded in 1995 and is headquartered in Montreal, Canada. | Corporate Officer/Principal | 01/01/1997 |
Thrasos Therapeutics, Inc.
 Thrasos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Thrasos Therapeutics, Inc. operates as a clinical-stage biotherapeutics company which focuses on bringing new solutions to kidney disease patients. It develops novel approaches to protect, treat and restore kidney function for this underserved patient group. The firms products include THR-184 to prevent AKI associated with cardiac surgery, THR-204 to treat certain forms of CKD, and the THR-800 series to treat cast nephropathy, a form of AKI associated with multiple myeloma. The company was founded by William D. Carlson and Murty Bosukonda in 2003 and is headquartered in Montreal, Canada. | Directeur/Membre du Conseil | - |
| MIRATI THERAPEUTICS | Directeur/Membre du Conseil | 01/05/2009 |
Formation de Gaétan Gravel
| HEC Montréal | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 5 |
|---|---|
Mirati Therapeutics, Inc.
 Mirati Therapeutics, Inc. BiotechnologyHealth Technology Mirati Therapeutics, Inc. operates as a clinical-stage oncology company. engages in the development of novel therapeutics. The firm's products target the genetic and immunological promoters of cancer. Its clinical pipeline consists of Adagrasib, MRTX1133, and Sitravatinib. The company was founded on December 13, 1995, and is headquartered in San Diego, CA. | Health Technology |
Business Development Bank of Canada
Business Development Bank of Canada Finance/Rental/LeasingFinance Business Development Bank of Canada provides commercial banking services. It offers business loans and consulting services to help Canadian businesses grow, both at home and abroad. The firm also offers a full spectrum of specialized financing, including venture capital, equity as well as growth and business transition capital through its subsidiaries. The company was founded in 1995 and is headquartered in Montreal, Canada. | Finance |
Fonds de Solidarité FTQ
Fonds de Solidarité FTQ Investment ManagersFinance Fonds de Solidarité FTQ (Fonds Régional de Solidarité FTQ) is a private equity firm founded in June 1983. The firm is headquartered in Montréal, Quebec. | Finance |
Thrasos Therapeutics, Inc.
Thrasos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Thrasos Therapeutics, Inc. operates as a clinical-stage biotherapeutics company which focuses on bringing new solutions to kidney disease patients. It develops novel approaches to protect, treat and restore kidney function for this underserved patient group. The firms products include THR-184 to prevent AKI associated with cardiac surgery, THR-204 to treat certain forms of CKD, and the THR-800 series to treat cast nephropathy, a form of AKI associated with multiple myeloma. The company was founded by William D. Carlson and Murty Bosukonda in 2003 and is headquartered in Montreal, Canada. | Health Technology |
GLyPharma Therapeutic, Inc.
GLyPharma Therapeutic, Inc. BiotechnologyHealth Technology GLyPharma Therapeutic, Inc. develops oncology therapeutic treatment. It engages in the development of the clinical efficacy of FE 203799, a novel proprietary Glucagon-Like Peptide-2(GLP-2) analogue exerting unique pharmacological effects in a first-in-class, meaningful indication for patients with hematological malignancies receiving myelotoxic therapies. The company was founded in August 2012 and is headquartered in Montreal, Canada. | Health Technology |
